JNJ
Johnson & Johnson
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Johnson & Johnson.
$243.04-1.40 (-0.57%)● Live
Current Narrative
J&J is seen as a strong buy with oncology growth potentially doubling and resilient healthcare fundamentals. Insider sales of 22.8M shares noted, but biopharma sentiment surge (BPSI 78→90) and structural tailwinds are positive. Market views as stable amid corrections with strong long-term growth guidance.
News
Latest Coverage
NewsFeb 3
Strong Buy on JNJ at $228.26
Insiders cashing out 22.8M shares; technical target $148.29, consensus $230.63.
@CapitalWisdomAI on X
NewsJan 30
Johnson & Johnson Guidance
Guides significant oncology sales growth, potentially doubling near-term; supports strong long-term growth.
@MultibaggAIHQ on X
NewsJan 28
Biopharma Sentiment Snapped Higher
BPSI index jumped 78 to 90; aligns with price action and deal flow—continued M&A/IPOs expected.
@BowTiedBiotech on X
NewsJan 27
Hospitals in Correction Mode
Stocks down 20-30%; focus on below 20x EV/EBITDA with 20%+ growth—structural tailwind intact.
@EquityInsightss on X
Rule of 402025 Q3
40.5
✓ Passing
Revenue Growth YoY+6.8%
+
FCF Margin+33.7%
History
2023 R40 +28
2024 R40 +27
Company timeline
Earnings release dates
| Quarter | End date | Publication date | Source |
|---|---|---|---|
| 2025 Q4 | 2025-12-31 | 2026-01-21 | Link |
| 2025 Q3 | 2025-09-30 | 2025-10-14 | Link |
| 2025 Q2 | 2025-06-30 | 2025-07-16 | Link |
| 2025 Q1 | 2025-03-31 | 2025-04-15 | Link |
| 2024 Q4 | 2024-12-31 | 2025-01-22 | Link |
| 2024 Q3 | 2024-09-30 | 2024-10-15 | Link |
| 2024 Q2 | 2024-06-30 | 2024-07-17 | Link |
| 2024 Q1 | 2024-03-31 | 2024-04-16 | Link |
| 2023 Q4 | 2023-12-31 | 2024-01-23 | Link |
| 2023 Q3 | 2023-09-30 | 2023-10-17 | Link |
| 2023 Q2 | 2023-06-30 | 2023-07-20 | Link |
| 2023 Q1 | 2023-03-31 | 2023-04-18 | Link |
| 2022 Q4 | 2022-12-31 | 2023-01-24 | Link |
| 2022 Q3 | 2022-09-30 | 2022-10-18 | Link |
| 2022 Q2 | 2022-06-30 | 2022-07-19 | Link |
| 2022 Q1 | 2022-03-31 | 2022-04-19 | Link |
| 2021 Q4 | 2021-12-31 | 2022-01-25 | Link |
| 2021 Q3 | 2021-09-30 | 2021-10-19 | Link |
| 2021 Q2 | 2021-06-30 | 2021-07-21 | Link |
| 2021 Q1 | 2021-03-31 | 2021-04-20 | Link |
| 2020 Q4 | 2020-12-31 | 2021-01-26 | Link |
| 2020 Q3 | 2020-09-30 | 2020-10-13 | Link |
| 2020 Q2 | 2020-06-30 | 2020-07-16 | Link |
| 2020 Q1 | 2020-03-31 | 2020-04-14 | Link |
Background
Company History
ExchangeNYSE
IPO DateSep 25, 1944
Shares Outstanding2.43Bi
1886
Founding of Johnson & Johnson
Three brothers founded the company in New Brunswick, New Jersey, producing ready-to-use sterile surgical dressings with 14 employees.
1888
Launch of First Commercial First Aid Kit
Designed to support railroad workers far from medical care, including antiseptic supplies and field use directions.
1920
Invention of Band-Aid
Earle Dickson combined adhesive tape and gauze to create the first commercial adhesive bandage, sold starting 1921.
1943
Creation of the Credo
Robert Wood Johnson wrote
1982
Tylenol Murders Crisis
Cyanide-laced Tylenol led to a nationwide recall of 31 million bottles; company response set industry standards for crisis management.
2017
Acquisition of Actelion
$30 billion deal, the largest in company history, expanding pharmaceutical capabilities.
2022
Acquisition of Abiomed
$16.6 billion purchase of cardiovascular medical technology company to bolster MedTech segment.
2023
Spin-Off of Kenvue
Consumer health division went public as Kenvue in May 2023, with J&J retaining minimal stake by 2024.
2025
Intra-Cellular Therapies Acquisition
Acquired Intra-Cellular Therapies for $14.6B in January 2025, continuing aggressive M&A strategy.
Leadership
Key Players
Joaquin Duato
Chairman & Chief Executive OfficerCEO since January 2022, Chairman since January 2023. Leads ~138,000 employees globally, directing an R&D portfolio of nearly $17B annually across pharmaceuticals and MedTech.
Joseph J. Wolk
Executive Vice President, Chief Financial OfficerOversees global finance, capital markets and investor relations. Maintains AAA-equivalent balance sheet with net debt-to-EBITDA under 1.5x.
Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative MedicineLeads commercial strategy for ten blockbuster therapies generating ~$57B in sales across oncology, immunology, neuroscience, and cardiology.
Tim Schmid
Executive Vice President, Worldwide Chairman, MedTechRuns $30B+ medical-technology portfolio spanning 300+ platforms and 8,000 patents, including surgical robotics and AI-guided endoscopy.
John C. Reed
Executive Vice President, Innovative Medicine, R&DM.D., Ph.D. Directs end-to-end drug discovery pipeline with 105 clinical assets including 40 in Phase 3. Integrates AI-enabled research and 400 academic/biotech partners.
Vanessa Broadhurst
Executive Vice President, Global Corporate AffairsLeads corporate marketing, communications, health-equity initiatives and philanthropy across 100+ markets.
Short Interest
Short interest data unavailable for JNJ.
